Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 3/20 | 0.46 |
| ▸ | MME | P08473 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14921504 | 0.83 | CTSS (0.49) | CTRB1MMECYP3A4MAPK1NPC1 | |
| SCHEMBL2973301 | 0.79 | MAPK1 (0.68) | CTRB1MMECYP3A4MAPK1NPC1 | |
| SCHEMBL3959317 | 0.79 | MAPK1 (0.68) | CTRB1MMECYP3A4MAPK1NPC1 | |
| SCHEMBL3897966 | 0.79 | MAPK1 (0.68) | CTRB1MMECYP3A4MAPK1NPC1 | |
| SCHEMBL2543478 | 0.77 | HPGD (0.60) | CTRB1MMECYP3A4MAPK1NPC1 | |
| SCHEMBL3730596 | 0.77 | CTRB1 (0.50) | CTRB1MMECYP3A4MAPK1NPC1 | |
| SCHEMBL14320632 | 0.77 | CTRB1 (0.50) | CTRB1MMECYP3A4MAPK1NPC1 | |
| SCHEMBL21628079 | 0.77 | MME (0.50) | CTRB1MMECYP3A4MAPK1NPC1 | |
| SCHEMBL9272431 | 0.77 | HPGD (0.60) | CTRB1MMECYP3A4MAPK1NPC1 | |
| SCHEMBL8837460 | 0.77 | MME (0.73) | CTRB1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584759-B2 | Macrocyclic kinase inhibitor | HITGEN INC. (CN) | 2023-02-21 | — | — | US | disclosed |
| EP-3783000-B1 | MACROCYCLIC KINASE INHIBITOR | HITGEN INC (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-20210147443-A1 | MACROCYCLIC KINASE INHIBITOR | HITGEN INC. (CN) | 2021-05-20 | — | — | US | disclosed |
| EP-3783000-A1 | MACROCYCLIC KINASE INHIBITOR | Hitgen Inc. (CN) | 2021-02-24 | — | — | EP | disclosed |
| US-20170281620-A1 | CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY | PARION SCIENCES, INC. (US) | 2017-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210147443-A1 | MACROCYCLIC KINASE INHIBITOR | MAP3K20, TNK2, NTRK1 | CTRB1 3634/4885MME 3430/4885CYP3A4 4787/4885 |
| US-20170281620-A1 | CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY | CACNA1B, SCN1B, KCNB1 | CTRB1 923/4885MME 298/4885CYP3A4 988/4885 |
| US-11584759-B2 | Macrocyclic kinase inhibitor | MAP3K20, TNK2, NTRK1 | CTRB1 3634/4885MME 3430/4885CYP3A4 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.